You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,414,044


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,414,044
Title:Use of targeted oxidative therapeutic formulation in treatment of type 2 diabetes
Abstract: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (\"DMSO\"); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with diabetes and obesity.
Inventor(s): Hofmann; Robert F. (Austin, TX)
Assignee:
Application Number:11/122,907
Patent Claims:1. A method for treating a patient with Type 2 diabetes comprising: administering to the patient an effective amount of a pharmaceutical formulation comprising: peroxidic species or reaction products resulting from oxidation of an alkene by an oxygen-containing oxidizing agent, wherein the alkene is selected from the group consisting of .alpha.-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, geranylgeraniol and farnesol, wherein the oxygen-containing oxidizing agent is selected from the group consisting of singlet oxygen, oxygen in its triplet state, superoxide anion, periodate, hydroxyl radical, hydrogen peroxide, alkyl peroxide, carbamyl peroxide, benzoyl peroxide, and oxygen bound to a transition element, and wherein the peroxidic species or reaction products resulting from oxidation of the alkene is from about 0.001% to about 30% by weight of the pharmaceutical formulation; a penetrating solvent, wherein the penetrating solvent is selected from the group consisting of dimethylsulfoxide, sterol, lecithin, propylene glycol, and methylsulfonylmethane, and wherein the penetrating solvent is from about 50% to about 99% by weight of the pharmaceutical formulation; a dye containing a chelated divalent or trivalent metal, wherein the dye is selected from the group consisting of porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, fluorescein, phthalocyanine, eumelanin, and pheomelanin, and wherein the dye is from about 0.1% to about 30% by weight of the pharmaceutical formulation; and an aromatic redox compound, wherein the redox compound is selected from the group consisting of substituted or unsubstituted benzoquinone, naphthoquinone, and anthroquinone, and wherein the aromatic redox compound is from about 0.01% to about 20% by weight of the pharmaceutical formulation.

2. The method of claim 1, wherein the alkene is in a liquid form, in a solution, or in a dispersion.

3. The method of claim 1, wherein the alkene is contained in a fixed oil, an ester, a fatty acid, or an ether.

4. The method of claim 1, wherein the oxygen-containing oxidizing agent comprises ozone.

5. The method of claim 1, wherein the penetrating solvent is a liquid, micelle membrane, emollient, or vapor.

6. The method of claim 1, wherein the penetrating solvent is dimethylsulfoxide ("DMSO").

7. The method of claim 1, wherein the dye is selected from the group consisting of porphyrin, rose bengal, chlorophyllin, and a mixture thereof.

8. The method of claim 1, wherein the metal comprises iron.

9. The method of claim 1, wherein the metal is selected from the group consisting of copper, manganese, tin, magnesium, and strontium.

10. The method of claim 1, further comprising an electron donor.

11. The method of claim 10, wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.

12. A method for treating a patient with Type 2 diabetes comprising: administering to the patient an effective amount of a pharmaceutical formulation comprising: peroxidic species or reaction products resulting from oxidation of geraniol by a mixture of ozone and oxygen; dimethylsulfoxide ("DMSO"); a dye containing a chelated divalent or trivalent metal, wherein the dye comprises a mixture of hematoporphyrin and rose bengal or a mixture of hematoporphyrin and chlorophyllin; and methylnaphthoquinone.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.